New drug aims to cut transfusions for MDS patients
NCT ID NCT07319845
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study tests a drug called TAK-226 (Elritercept) in 27 Japanese adults with lower-risk myelodysplastic syndromes (MDS) who need regular blood transfusions. The goal is to see if the drug can help them go without transfusions for at least 8 weeks. Participants will receive injections every few weeks and be followed for up to 6 years to check for side effects and long-term benefits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-226 (also called Elritercept or KER-050), given as a shot under the skin
- What this could lead to
- If it works, this could help people with lower-risk MDS need fewer blood transfusions, improving their quality of life.
- What could go wrong
- This is an early phase 2 study with only 27 people, so results may not apply to everyone. It is not yet known if TAK-226 is safe or effective long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dokkyo Medical University Hospital
NOT_YET_RECRUITINGTochigi, Mibu, Japan
-
Gifu Municipal Hospital
NOT_YET_RECRUITINGGifu, Japan
-
Hokuyukai Sapporo Hokuyu Hospital
RECRUITINGHokkaido, Sapporo, Japan
-
JCHO Kyushu Hospital
NOT_YET_RECRUITINGFukuoka, Kitakyushu, Japan
-
Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital
NOT_YET_RECRUITINGHiroshima, Fukuyama, Japan
-
Japanese Red Cross Nagasaki Genbaku Hospital
NOT_YET_RECRUITINGNagasaki, Japan
-
Japanese Red Cross Narita Hospital
NOT_YET_RECRUITINGChiba, Narita, Japan
-
Kindai University Hospital
NOT_YET_RECRUITINGOsaka, Sakai, Japan
-
Kitasato University Hospital
NOT_YET_RECRUITINGKanagawa, Sagamihara, Japan
-
Kobe City Hospital Organization Kobe City Medical Center General Hospital
NOT_YET_RECRUITINGHyōgo, Kobe, Japan
-
Matsuyama Red Cross Hospital
NOT_YET_RECRUITINGEhime, Matsuyama, Japan
-
NTT Medical Center Tokyo
RECRUITINGTokyo, Shinagawa-ku, Japan
-
National Hospital Organization Kyushu Medical Center
NOT_YET_RECRUITINGFukuoka, Japan
-
National Hospital Organization Nagoya Medical Center
NOT_YET_RECRUITINGAichi, Nagoya, Japan
-
National University Corporation Tohoku University Tohoku University Hospital
NOT_YET_RECRUITINGMiyagi, Sendai, Japan
-
Okayama City General Medical Center Okayama City Hospital
NOT_YET_RECRUITINGOkayama, Japan
-
Tokai University Hospital
NOT_YET_RECRUITINGKanagawa, Isehara, Japan
-
Tokyo Metropolitan Komagome Hospital
NOT_YET_RECRUITINGTokyo, Bunkyo-ku, Japan
-
University of Fukui Hospital
NOT_YET_RECRUITINGFukui, Eiheiji, Japan
-
Yamanashi Prefectural Central Hospital
NOT_YET_RECRUITINGYamanashi, Kofu, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that mimics the body's oxygen sensor may free MDS patients from frequent blood transfusions
- Drug combo aims to break anemia cycle in MDS patients
- Gene mapping of childhood blood cancers could unlock personalized treatments
- Epigenetic drugs aim to stop cancer return after transplant in kids
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
- Can a website ease the emotional toll of stem cell transplants?